$15.90
Manufacturer: Ukraine
Short-term treatment of moderate-intensity pain syndrome, especially in the postoperative period, and short-term treatment of hyperthermic reactions, when intravenous use is clinically justified or other methods of application are unacceptable.
Description
Infulgan solution Composition
active substance: paracetamol;
1 ml of solution contains paracetamol 10 mg;
excipients: citric acid monohydrate, sodium; sorbitol (E 420) sodium sulfite anhydrous (E 221) water for injection.
Infulgan solution Dosage form
Solution for infusion.
Basic physical and chemical properties: transparent, colorless or slightly yellowish solution.
Infulgan solution Pharmacotherapeutic group
Analgesics and antipyretics. ATX code N02B E01.
Pharmacodynamics
Adults
Infulgan (paracetamol) has analgesic and antipyretic effects. Paracetamol blocks cyclooxygenase (COX) I and II only in the central nervous system, affecting the centers of pain and thermoregulation. In inflamed tissues, cellular peroxidases neutralize the effect of paracetamol on COX, which explains the almost complete absence of the anti-inflammatory effect. The lack of effect on the synthesis of prostaglandins in peripheral tissues causes the drug to have no negative effect on water-salt metabolism (sodium and water retention) and the mucous membrane of the digestive tract.
Pharmacokinetics
Infulgan provides pain relief 5-10 minutes after administration. The peak of the analgesic effect is reached within 1 hour, and the duration of this effect is usually 4-6 hours.
Infulgan reduces body temperature within 30 minutes after administration, the antipyretic effect lasts for at least 6 hours.
Suction
After a single use of up to 2 g of the drug and after repeated use within 24 hours, the pharmacokinetics of paracetamol is linear.
Bioavailability after infusion of 500 mg and 1 g of paracetamol is the same as after administration of 1 g and 2 g of propacetamol (containing 500 mg and 1 g of paracetamol, respectively). The maximum concentration (Cmax) in blood plasma is reached at the end of the infusion of 15 minutes duration of 500 mg or 1 g of paracetamol and is 15 μg / ml or 30 μg / ml, respectively.
Distribution
The volume of distribution of paracetamol is about 1 L / kg. Paracetamol weakly binds to blood plasma proteins. After the introduction of 1 g of paracetamol, a significant level of concentration (about 1.5 μg / ml) was established in the cerebrospinal fluid 20 minutes after the infusion.
Indications
Short-term treatment of pain syndrome of moderate intensity, especially in the postoperative period, and short-term treatment of hyperthermic reactions, when intravenous use is clinically justified or other methods of use are unacceptable.
Contraindications
Hypersensitivity to paracetamol, propacetamol hydrochloride (a precursor of paracetamol) or other components of the drug. Severe hepatocellular insufficiency.
Interaction with other medicinal products and other types of interactions
Probenecid halves the clearance of paracetamol by blocking its binding with glucuronic acid, therefore, when combined therapy with probenecid, the dose of paracetamol should be reduced.
Salicylates can increase the half-life of paracetamol from the body.
Inducers of microsomal oxidation in the liver (phenytoin, ethanol, barbiturates, rifampicin, phenylbutazone, tricyclic antidepressants) can contribute to the development of severe intoxication even with a small overdose.
The simultaneous use of paracetamol (4 g per day for at least 4 days) with oral anticoagulants can lead to minor changes in the international normalized ratio (INR). In this case, the INR should be monitored during treatment and within 1 week after completion of treatment with Infulgan.
Recent Reviews